Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptophan SCHEMBL4274128 | 0.87 | KMT2A (0.65) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL3327576 | 0.83 | KMT2A (0.97) | KMT2AKDM4EMAPTLMNATSHR | |
| D-Tryptophan SCHEMBL10492072 | 0.83 | KMT2A (0.97) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL27748750 | 0.82 | KDM4E (0.94) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL27748748 | 0.82 | KDM4E (0.94) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL28580277 | 0.82 | KDM4E (0.94) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL10929235 | 0.82 | KMT2A (0.94) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL23141133 | 0.82 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL475349 | 0.82 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL7327 | 0.82 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156795-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DRUG RESISTANT TOPICAL INFECTIONS | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2024-05-16 | — | — | US | claimed |
| EP-3731841-A1 | COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF | Evergreen Biosciences (US) | 2020-11-04 | — | — | EP | claimed |
| CN-111655258-A | Compositions for cryopreservation and methods of use thereof | 常青树生物科学公司 | 2020-09-11 | — | — | CN | claimed |
| US-20200199242-A1 | CONSTRUCT-PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | ORBIMED ADVISORS LLC | 2020-06-25 | — | — | US | claimed |
| US-20190336615-A1 | TUMOR TARGETING CONJUGATES AND METHODS OF USE THEREOF | ORBIMED ADVISORS LLC | 2019-11-07 | — | — | US | claimed |
| US-20190201381-A1 | COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF | EVERGREEN BIOSCIENCES (US) | 2019-07-04 | — | — | US | claimed |
| WO-2018144955-A1 | CONSTRUCT-PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2018-08-09 | — | — | WO | claimed |
| WO-2018140831-A2 | TUMOR TARGETING CONJUGATES AND METHODS OF USE THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2018-08-02 | — | — | WO | claimed |
| WO-2010008427-A1 | TRYPTOPHAN CATABOLISM IN CANCER TREATMENT AND DIAGNOSIS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2010-01-21 | — | — | WO | claimed |
| US-12605469-B2 | Tumor specific antibody conjugates and uses therefor | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2026-04-21 | — | — | US | disclosed |
| CN-111655258-B | Compositions for cryopreservation and methods of use thereof | 常青树生物科学公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12059429-B2 | Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-08-13 | — | — | US | disclosed |
| US-12053454-B2 | Compositions for cryopreservation and methods of use thereof | EVERGREEN BIOSCIENCES (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2024124311-A1 | PLP2-DERIVED PEPTIDES, PHARMACEUTICAL COMPOSITIONS, METHODS AND USES OF THEREOF | RECEPTA BIOPHARMA S.A. (BR) | 2024-06-20 | — | — | WO | disclosed |
| US-20100081699-A1 | YEAST PLATFORM CONSTRUCTION AND SCREENING METHODS | Bioalvo-Servicos ,Investigacao e Desenvolvimento em Biotlecnologia S.A. (PT) | 2010-04-01 | — | — | US | disclosed |
| CN-101674826-A | Chemical compound, screening and Therapeutic Method | HARVARD COLLEGE | 2010-03-17 | — | — | CN | disclosed |
| EP-2102333-A2 | YEAST PLATFORM CONSTRUCTION AND SCREENING METHODS | Bioalvo - Serviços, Investigação E Desenvolvimento Em Biotecnologia S.A. (PT) | 2009-09-23 | — | — | EP | disclosed |
| EP-1968583-A2 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008075991-A2 | YEAST PLATFORM CONSTRUCTION AND SCREENING METHODS | BIOALVO - SERVIÇOS, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA S.A. (PT) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007075772-A2 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081699-A1 | YEAST PLATFORM CONSTRUCTION AND SCREENING METHODS | NQO1, NADK, SARM1 | KMT2A 1959/4885KDM4E 2732/4885MAPT 4027/4885 |
| US-20190336615-A1 | TUMOR TARGETING CONJUGATES AND METHODS OF USE THEREOF | CD47, CD74, CD44 | KMT2A 2778/4885KDM4E 3661/4885MAPT 4029/4885 |
| US-12053454-B2 | Compositions for cryopreservation and methods of use thereof | BAK1, BAX, BAD | KMT2A 3977/4885KDM4E 1793/4885MAPT 2314/4885 |
| US-20190201381-A1 | COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF | BAX, BAK1, CASP3 | KMT2A 4234/4885KDM4E 3010/4885MAPT 2298/4885 |
| US-12605469-B2 | Tumor specific antibody conjugates and uses therefor | MUC1, CD47, CD44 | KMT2A 2400/4885KDM4E 3288/4885MAPT 1729/4885 |
| US-20200199242-A1 | CONSTRUCT-PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | NGLY1, MICA, VIP | KMT2A 4123/4885KDM4E 4520/4885MAPT 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.